You just read:

First-in-Class Anti-CGRP Monoclonal Antibodies for Migraine Prevention from Eli Lilly, Teva, Amgen/Novartis, and Alder will Drive Market Growth Through 2025

News provided by

Decision Resources Group

Sep 27, 2016, 09:00 ET